Mostrar el registro sencillo del ítem

Cost-effectiveness of AQP4 antibody detection with cell-based assay compared with elisa for devic disease diagnosis in Colombia

dc.contributorPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Enfermedades Crónicas del Adulto
dc.creatorRosselli, Diego
dc.creatorAcosta, A.
dc.creatorCastañeda, C.
dc.creatorRuiz Patiño, Alejandro
dc.creatorRuiz, R.
dc.date2020-04-16T14:01:57Z
dc.date2020-05-08T15:22:21Z
dc.date2020-04-16T14:01:57Z
dc.date2020-05-08T15:22:21Z
dc.date2015-05-01
dc.date.accessioned2025-10-30T14:03:21Z
dc.date.available2025-10-30T14:03:21Z
dc.identifierhttps://www.valueinhealthjournal.com/article/S1098-3015(15)00316-2/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301515003162%3Fshowall%3Dtrue#%20
dc.identifier1524-4733 / 1098-3015 (Electrónico)
dc.identifierhttp://hdl.handle.net/10554/48237
dc.identifierhttp://doi.org/10.1016/j.jval.2015.03.259
dc.identifier.urihttp://test.repositoriodigital.com:8080/handle/123456789/193130
dc.descriptionQ1
dc.descriptionQ1
dc.descriptionA44
dc.descriptionObjectives Neuromyelitis optica (NMO) or Devic disease is a rare chronic condition characterized by demyelinating lesions in the central nervous system. The aim of this study was to evaluate cost-effectiveness of the detection of antibodies against the protein aquaporin water channel 4 (AQP4) with cell-based assay (CBA), compared with ELISA, for the diagnosis of NMO in Colombia. Methods A decision tree model was constructed to compare costs, correctly diagnosed cases and relapses averted in patients with clinical suspicion of NMO, that were subjected to diagnostic tests for the detection of AQP4 antibodies. The analysis was undertaken from a third-party payer perspective, one year time horizon (first year with the disease) taking all costs for treatment and relapses, in 2014 Colombian pesos, from official published prices (1 USD = 2,033 COP). Since the CBA kit is not available in Colombia (currently samples are processed abroad), the price was obtained from the manufacturer and set in a national laboratory. Clinical variables were from a systematic literature review. Univariate and probabilistic sensitivity analyses (a Monte Carlo simulating a cohort of 1000 patients) were conducted. Results Identification of AQP4 antibodies with CBA is a dominant strategy: more effective (855 correctly diagnosed patients compared with 765 detected by ELISA, and 130 avoided relapses), and less costly, with expected yearly costs per correctly diagnosed Devic patient of USD $14,658 compared with $15,614 for ELISA. Using CBA may represent savings in terms of reduced costs of treating disease and relapse with hospitalization. Conclusions AQP4 antibody identification by the CBA method is a cost-saving diagnostic test, dominant over the ELISA method.
dc.formatPDF
dc.formatapplication/pdf
dc.formatPapel / Electrónico
dc.formatapplication/pdf
dc.languagespa
dc.rightsAtribución-NoComercial 4.0 Internacional
dc.rightshttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceValue in Health; Vol. 18 Núm. 3 (2015)
dc.titleCost-effectiveness of AQP4 antibody detection with cell-based assay compared with elisa for devic disease diagnosis in Colombia
dc.typeinfo:eu-repo/semantics/article
dc.typehttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.typeArtículo de revista
dc.coverageColombia


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem